A Case of Persistent Pityriasis Rosea Successfully Treated by a Short Course of Therapy with Abrocitinib

Abstract

Pityriasis rosea (PR) is a common inflammatory, erythematous and scaly skin condition that usually affects individuals aged from 20 to 40 years old. The disease often exhibits a self-limiting course up to 6-8 weeks. We report a 25-year-old female patient with a six-month history of red scaly rashes on the trunk and proximal limbs, accompanied by severe pruritus that has been remained ineffective conventional treatments. She was diagnosed as persistent pityriasis rosea. As abrocitinib has been proved to be effective for many inflammatory diseases, therefore in this case, we tried abrocitinib for the patient, and a good result had been achieved.

Pityriasis Rosea and Immunosuppressive Drugs [Letter]

“…We read with great interest the paper of Wu et al about a case of persistent pityriasis rosea (PPR) successfully treated by a short course of therapy with abrocitinib 1 that allows us to make a few observations. The authors diagnosed the patient’s eruption as PPR but, though Auspitz sign was negative, the possibility of a psoriasiform eruption should be considered in the differential diagnosis.…”